227 related articles for article (PubMed ID: 28726401)
21. Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors.
Pryce G; Baker D
Br J Pharmacol; 2007 Feb; 150(4):519-25. PubMed ID: 17220914
[TBL] [Abstract][Full Text] [Related]
22. Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(α)], an N-terminally extended hemopressin peptide.
Han ZL; Fang Q; Wang ZL; Li XH; Li N; Chang XM; Pan JX; Tang HZ; Wang R
J Pharmacol Exp Ther; 2014 Feb; 348(2):316-23. PubMed ID: 24307201
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands.
Davis MP
Expert Opin Investig Drugs; 2014 Aug; 23(8):1123-40. PubMed ID: 24836296
[TBL] [Abstract][Full Text] [Related]
24. Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135.
De Luca MA; Castelli MP; Loi B; Porcu A; Martorelli M; Miliano C; Kellett K; Davidson C; Stair JL; Schifano F; Di Chiara G
Neuropharmacology; 2016 Jun; 105():630-638. PubMed ID: 26686391
[TBL] [Abstract][Full Text] [Related]
25. Differential effects of cannabinoid receptor agonists on regional brain activity using pharmacological MRI.
Chin CL; Tovcimak AE; Hradil VP; Seifert TR; Hollingsworth PR; Chandran P; Zhu CZ; Gauvin D; Pai M; Wetter J; Hsieh GC; Honore P; Frost JM; Dart MJ; Meyer MD; Yao BB; Cox BF; Fox GB
Br J Pharmacol; 2008 Jan; 153(2):367-79. PubMed ID: 17965748
[TBL] [Abstract][Full Text] [Related]
26. Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development.
Ford BM; Franks LN; Radominska-Pandya A; Prather PL
PLoS One; 2016; 11(12):e0167240. PubMed ID: 27936172
[TBL] [Abstract][Full Text] [Related]
27. Strategies to develop selective CB
Moir M; Lane S; Lai F; Connor M; Hibbs DE; Kassiou M
Eur J Med Chem; 2019 Oct; 180():291-309. PubMed ID: 31319265
[TBL] [Abstract][Full Text] [Related]
28. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
[TBL] [Abstract][Full Text] [Related]
29. Crystal Structure of the Human Cannabinoid Receptor CB2.
Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
[TBL] [Abstract][Full Text] [Related]
30. Two Janus Cannabinoids That Are Both CB2 Agonists and CB1 Antagonists.
Dhopeshwarkar A; Murataeva N; Makriyannis A; Straiker A; Mackie K
J Pharmacol Exp Ther; 2017 Feb; 360(2):300-311. PubMed ID: 27927913
[TBL] [Abstract][Full Text] [Related]
31. Selective CB2 agonists with anti-pruritic activity: discovery of potent and orally available bicyclic 2-pyridones.
Kusakabe K; Iso Y; Tada Y; Sakagami M; Morioka Y; Chomei N; Shinonome S; Kawamoto K; Takenaka H; Yasui K; Hamana H; Hanasaki K
Bioorg Med Chem; 2013 Jun; 21(11):3154-63. PubMed ID: 23623258
[TBL] [Abstract][Full Text] [Related]
32. Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis.
Annunziata P; Cioni C; Mugnaini C; Corelli F
J Neuroimmunol; 2017 Feb; 303():66-74. PubMed ID: 28041663
[TBL] [Abstract][Full Text] [Related]
33. Synthetic cannabinoid receptor agonists: classification and nomenclature.
Potts AJ; Cano C; Thomas SHL; Hill SL
Clin Toxicol (Phila); 2020 Feb; 58(2):82-98. PubMed ID: 31524007
[No Abstract] [Full Text] [Related]
34. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
[TBL] [Abstract][Full Text] [Related]
35. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors.
Muccioli GG; Lambert DM
Curr Med Chem; 2005; 12(12):1361-94. PubMed ID: 15974990
[TBL] [Abstract][Full Text] [Related]
36. Identification of CB1/CB2 ligands from Zanthoxylum bungeanum.
Dossou KS; Devkota KP; Morton C; Egan JM; Lu G; Beutler JA; Moaddel R
J Nat Prod; 2013 Nov; 76(11):2060-4. PubMed ID: 24175626
[TBL] [Abstract][Full Text] [Related]
37. Activation of cannabinoid receptor 2 inhibits experimental cystitis.
Wang ZY; Wang P; Bjorling DE
Am J Physiol Regul Integr Comp Physiol; 2013 May; 304(10):R846-53. PubMed ID: 23515618
[TBL] [Abstract][Full Text] [Related]
38. Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
Han S; Zhang FF; Qian HY; Chen LL; Pu JB; Xie X; Chen JZ
J Med Chem; 2015 Aug; 58(15):5751-69. PubMed ID: 26151231
[TBL] [Abstract][Full Text] [Related]
39. Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model.
Ni X; Geller EB; Eppihimer MJ; Eisenstein TK; Adler MW; Tuma RF
Mult Scler; 2004 Apr; 10(2):158-64. PubMed ID: 15124761
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists.
Cascio MG; Bolognini D; Pertwee RG; Palazzo E; Corelli F; Pasquini S; Di Marzo V; Maione S
Pharmacol Res; 2010 Apr; 61(4):349-54. PubMed ID: 19961936
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
